Executives Highlight Expansion Plans at the DCAT Member Company Announcement Forum
By

Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week with the latest in expansion plans across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). Which companies are making the news?

Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week with the latest in expansion plans across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). Which companies are making the news?

Below are the news announcements from companies taking to the podium at the DCAT Member Company Announcement Forum held on March 20, 2023, at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT). A further roundup of other DCAT Member Companies making the news thus far in 2023 will be featured in the April 7, 2023, issue of DCAT Value Chain Insights.

Recent Feature Articles

Bio/Pharma’s Top 10: Top Deals Thus Far in 2023
By

By
Analysis of the top 10 mergers and acquisitions among bio/pharmaceutical companies thus far in 2023. Which companies and deals are most noteworthy and leading the way? 

Sustainability: Measuring It Globally and in the C-Suite
By

By
How does sustainability and ESG (environmental, social and governance) goals and performance factor into companies’ strategies, operational focus, and financial disclosures? 

Teva’s President and CEO Launches New Pivot to Growth Strategy
By

By
Teva’s President and CEO, Richard Francis, who assumed the helm of Teva in January, outlined this week the company’s new strategic framework to drive growth. The company’s Pivot to Growth strategy encompasses four main pillars to deliver short- and long-term growth from the company’s commercial portfolio and biosimilars, innovative pipeline, generics business, and focused capital allocation. 

Tackling Drug Shortages and Supply-Chain Vulnerabilities in the European Union
By

By
Leaders in the European Union (EU) are addressing ways to mitigate drug shortages and supply-chain vulnerabilities in the EU with 19 EU member states supporting a Critical Medicines Act to reduce the EU’s dependence of non-EU countries for APIs, intermediates and other pharma ingredients. What other actions is the EU taking to mitigate supply-chain vulnerabilities?